<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>10981338</identifier>
<setSpec>0212-7199</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>del Valle Rivero, M L</dc:author>
<dc:author>Sanz Rubiales, A</dc:author>
<dc:author>Garavís Vicente, M</dc:author>
<dc:author>Rey Castro, P</dc:author>
<dc:author>López-Lara Martín, F</dc:author>
<dc:description xml:lang="en">Chemotherapy improves survival and achieves an impressive response rate, and, eventually, a percentage of long-term survivors in small-cell lung cancer. A possible way to a further improvement of these therapeutic outcomes is increasing chemotherapy dose-intensity. However, randomised comparative trials only show a slight improvement of results, with small clinical relevance. Prophylactic use of colony-stimulating factors decrease the incidence of neutropenia and neutropenic fever in comparative studies when an exceedingly myelotoxic chemotherapy regimen is used. And they also permit a little increase in chemotherapy dose-intensity without significant antineoplastic effect and almost no impact in overall survival. Nowadays, the administration of higher doses of chemotherapy in small-cell lung cancer still remains investigational in oncology.</dc:description>
<dc:type>Comparative Study</dc:type>
<dc:language>es</dc:language>
<dc:date>2000 Jul </dc:date>
<dc:title xml:lang="es">Intensidad de dosis de quimioterapia en carcinoma microcítico de pulmón. Revisión de estudios comparativos.</dc:title>
<dc:title xml:lang="en">[Dose intensity of chemotherapy in small-cell lung carcinoma. Review of comparative studies].</dc:title>
<dc:publisher>Anales de medicina interna (Madrid, Spain : 1984)</dc:publisher>
</metadata>
</record>
</pubmed-document>
